Press releases

Patient safety is always our highest priority at Boston Scientific.

"Meaningful innovation and focused execution helped us deliver strong financial results in 2018," said CEO Mike Mahoney.

Rezūm patients experienced significant and sustained improvement in benign prostatic hyperplasia (BPH) symptoms and quality of life.

Advanced systems offer customizable therapy to treat Parkinson's symptoms.

Boston Scientific venous stent met VIRTUS trial primary effectiveness and safety endpoints in re-establishing blood flow.

All patent litigation between the companies to be dismissed.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 2018 and the full 2018 year.

Boston Scientific will webcast its conference call discussing financial results and business highlights for Q4 ended December 31, 2018. Learn how to tune in.

Acquisition will expand structural heart portfolio to include transcatheter mitral annuloplasty repair system

A live webcast and replay will be available. Learn how to tune in.

Delaware court rules Edwards Lifesciences Infringes Boston Scientific patent

Boston Scientific will participate in a healthcare investor conference in December 2018. A live webcast and replay will be available.

Boston Scientific will participate in Citi’s healthcare investor conference in December 2018. A live webcast and replay will be available.

In helping care for people living with complex, debilitating and often life-threatening conditions, patient safety is Boston Scientific’s highest priority.

Boston Scientific will participate the healthcare investor conference in November 2018. A live webcast and replay will be available.

Transaction would expand Boston Scientific peripheral interventions portfolio with minimally invasive treatments for cancers and vascular conditions

Boston Scientific will participate in a medtech conference in November 2018. A live webcast and replay will be available.

Boston Scientific Corporation (NYSE: BSX) will participate in the Stifel 2018 Healthcare Conference on Tuesday, November 13, 2018 in New York City. Dan Brennan, executive vice president and chief...

Boston Scientific Corporation (NYSE: BSX) will participate in the 27th Annual Credit Suisse Healthcare Conference on Wednesday, November 14, 2018 in Scottsdale, Arizona. Joe Fitzgerald, executive...

"Through internal research and tuck-in acquisitions, we continue to bring meaningful innovations to market,” said CEO Mike Mahoney.

Court rules Edwards Lifesciences’ next-generation valve infringes Boston Scientific patent and grants right to enjoin sales in Germany.

The acquisition brings SpaceOAR, which decreases exposure to rectal radiation during prostate cancer radiotherapy, into the Boston Scientific portfolio.

Data support minimally invasive single-incision mesh procedure as a durable, safe and effective treatment for stress urinary incontinence.

4th annual Connected Patient Challenge focuses on using population health data, patient monitoring or predictive analytics to improve care and lower costs.

Boston Scientific will webcast its conference call with financial results and business highlights for Q3 ended September 30, 2018. Learn how to tune in.

Eluvia is the first peripheral vascular interventional technology approved in U.S. to offer a sustained release of a drug to treat peripheral artery disease.

First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries.

New data at World Congress of Endourology demonstrate the Lithovue Empower device for kidney stone retrieval improves the OR experience.

Key data will include results from IMPERIAL trial evaluating ELUVIA drug-eluting stent and from REPRISE III study evaluating LOTUS Aortic Valve System.

Acquisition expands Boston Scientific portfolio of men's health in-office procedures with SpaceOAR, an adjunctive therapy for prostate cancer patients.

Boston Scientific will participate in the upcoming healthcare conference in September 2018. A live webcast and replay will be available.

Boston Scientific will participate in the upcoming healthcare conference on Sept. 5, 2018. A live webcast and replay will be available.

Acquisition will bolster Boston Scientific peripheral interventions portfolio with a treatment for venous obstructive disease

Boston Scientific acquisition adds the Sentinel® Cerebral Protection System, the only device cleared to protect patients against stroke risk in TAVR procedures.

Boston Scientific will participate in the upcoming investor conference in August 2018. A live webcast and replay will be available.

"We're excited about the ways our differentiated pipeline will continue to drive our growth," said CEO Mike Mahoney.

Company does not endorse TRC's unsolicited mini-tender offer and recommends stockholders take no action.

Acquisition will add FDA-cleared Sentinel® Cerebral Embolic Protection System to expand Boston Scientific structural heart offerings.

Acquisition to expand Boston Scientific atrial fibrillation (Afib) ablation therapy offerings with innovative cryoballoon platform.

Boston Scientific will webcast its conference call with financial results for Q2 ended June 30, 2018. Learn how to tune in.

Key data to be presented at DDW include five-year outcomes after placement of the WallFlex™ RX Fully Covered Stent System RMV.

Key data will include results for patients treated with LOTUS™ Transcatheter Aortic Valve System and with the Agent™ drug coated balloon.

Boston Scientific will participate in the upcoming investor conference in May 2018. A live webcast and replay will be available.

The CBS network television show “60 Minutes” recently aired a segment with false claims. Read the facts about Boston Scientific pelvic floor products.

Data highlight the successful reduction of inappropriate shocks using the sensing filter in patients implanted with the EMBLEM™ S-ICD System.

Boston Scientific will participate in the upcoming healthcare conference on May 16, 2018. A live webcast and replay will be available.

Acquisition adds Rezūm®, a therapy for patients with symptomatic benign prostatic hyperplasia (BPH).

"Our consistently strong performance reflects our team's ongoing dedication,” said CEO Mike Mahoney.

Data demonstrated safety and effectiveness of VERCISE™ DBS System for controlling Parkinson’s symptoms.

European patent office revokes Edwards Lifesciences '550 patent.

Boston Scientific acquisition launches women's health focus on cancer and may lead to new diagnostic options for ovarian cancer.

Acquisition strengthens electrophysiology cardiac ablation portfolio with thermal monitor

U.K. court affirms that Edwards Lifesciences infringes Boston Scientific patent

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 ended March 31, 2018. Learn how to tune in.

Acquisition expands portfolio with minimally invasive treatment option for patients with benign prostatic hyperplasia

Data demonstrated RHYTHMIA™ Mapping System, paired with the INTELLAMAP ORION™ Mapping Catheter, safe and effective treatment for a variety of arrhythmias

Boston Scientific will participate in the upcoming healthcare conference on March 27, 2018. A live webcast and replay will be available.

Key data presentations at the European Heart Rhythm Association congress to include results for the RHYTHMIA™ Mapping System and the WATCHMAN™ device.

Boston Scientific will participate in the upcoming healthcare conference on March 27, 2018. A live webcast and replay will be available.

Acquisition expands endoscopic portfolio to include radiofrequency devices

Boston Scientific announced its completed public offering of senior notes.

Boston Scientific announced the pricing of a public offering of senior notes.

"Our team delivered excellent fourth quarter and full year results, said chairman and CEO Mike Mahoney.

Boston Scientific will participate in the upcoming healthcare conference on Feb. 15, 2018. A live webcast and replay will be available.

Suspending the medical device tax will allow the industry to reinvest in work to benefit patients

Millipede, Inc. is developing the IRIS Transcatheter Annuloplasty Ring System to treat severe mitral regurgitation

Boston Scientific will webcast its conference call discussing Q4 financial results and business highlights on Feb. 1, 2018 at the updated time of 7:30 a.m. EST.

Randomized controlled trial demonstrates effectiveness of long-term treatment with sub-perception spinal cord stimulation

System offers non-opioid treatment option with multiple therapies for people with chronic pain

Based upon preliminary unaudited financial information, the company generated approximately $2.41 billion in sales during Q4 2017.

Boston Scientific will participate in the upcoming healthcare conference on Jan. 9, 2018. A live webcast and replay will be available.

Boston Scientific will participate in the healthcare conference on Jan. 4, 2018. A live webcast and replay will be available.

DBS platform offers physicians advanced technology to treat symptoms of Parkinson's disease

Boston Scientific will participate in the healthcare conference on December 14, 2017. A live webcast and replay will be available.

Company announces delay for commercialization of the LOTUS Edge™ Aortic Valve System in Europe and the U.S.

Boston Scientific will participate in the healthcare conference on December 7, 2017. A live webcast and replay will be available.

Boston Scientific will participate in the healthcare conference on Nov. 28, 2017. A live webcast and replay will be available.

American Heart Association, American College of Cardiology and Heart Rhythm Society issue updated guidelines underscoring benefits of the S-ICD system

Boston Scientific will participate in the Stifel 2017 Healthcare Conference on November 14, 2017.

Boston Scientific will participate in the conference on November 7, 2017.

Late-breaking data presented at TCT 2017 with simultaneous publication in the Journal of the American College of Cardiology

“We continue to invest in a deep and innovative portfolio and expand into faster-growing markets," said CEO Mike Mahoney.

Key data presented will include five-year outcomes for the WATCHMAN device as an alternative to long-term warfarin therapy for patients with non-valvular Afib.

CEO Mike Mahoney welcomed Ralls-Morrison as “an accomplished leader with deep expertise in broad-ranging legal matters and enterprise business strategy.”

Acquisition to strengthen company's electrophysiology portfolio

Company will webcast its conference call with financial results and business highlights for Q3 ended September 30, 2017.

HeartLogic is the first and only heart failure diagnostic in an implantable device shown to provide weeks of advance notice of an impending heart failure event.

Data presented demonstrate alert improves heart failure risk prediction

Boston Scientific (NYSE: BSX) today announced results from a three year follow-up cohort in its Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma...

Boston Scientific will participate in the Morgan Stanley healthcare conference on Sept. 12, 2017. Learn how to watch the webcast or replay.

Boston Scientific will participate in the healthcare conference on September 7, 2017. Learn how to watch the webcast or replay.

Boston Scientific will participate in the investor conference on August 9, 2017. Learn how to watch the webcast or replay.

"Our strong financial performance in the first half of 2017 reflects our innovative portfolio,” said CEO Mike Mahoney.

Boston Scientific will webcast its conference call with financial results for Q2 ended June 30, 2017. Learn how to tune in or watch the replay.

Investor meeting will cover Boston Scientific’s business and long-term growth strategies, including by expanding category leadership and driving global growth.

Industry's first MR-conditional directional DBS System with stimulation visualization

Results from evaluation of real-world patients presented at American Thoracic Society International Conference

Boston Scientific will participate in the healthcare conference on May 23, 2017. Learn how to watch the webcast or replay.

The first head-to-head pivotal study comparing two different TAVI platforms demonstrated the LOTUS™ Valve System’s superior efficacy.

BAcquisition expands company's structural heart portfolio; increases offerings for the treatment of patients with valvular heart disease